Safety and efficacy of influenza vaccination in renal transplant recipients

Zand, Martin S.

doi:10.1038/ncpneph0830

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review found no increased risk of DSA development, rejection, or graft failure among vaccinated patients. These studies support the safety and efficacy of vaccination in transplant populations (178,187).…”

Section: Vaccinationsupporting

confidence: 70%

Bacterial infections in lung transplantation

McCort¹,

MacKenzie²,

Pursell³

et al. 2021

J Thorac Dis

View full text Add to dashboard Cite

Lung transplantation has lower survival rates compared to other than other solid organ transplants (SOT) due to higher rates of infection and rejection-related complications, and bacterial infections (BI) are the most frequent infectious complications. Excess morbidity and mortality are not only a direct consequence of these BI, but so are subsequent loss of allograft tolerance, rejection, and chronic lung allograft dysfunction due to bronchiolitis obliterans syndrome (BOS). A wide variety of pathogens can cause infections in lung transplant recipients (LTRs), including a number of nosocomial pathogens and other multidrug-resistant (MDR) pathogens. Although pneumonia and intrathoracic infections predominate, LTRs are at risk of a number of types of infections. Risk factors include altered anatomy and function of airways, impaired immunity, the microbial flora of the donor and recipient, underlying medical conditions, and genetic factors. Further work on immune monitoring has the potential to improve outcomes. The infecting agents can be derived from the donor lung, pre-existing recipient flora, or acquired from the environment over time. Certain infections may preclude lung transplantation, but this varies from center to center, and more recent studies suggest fewer patients should be disqualified. New molecular methods allow microbiome studies of the lung, gut, and other sites that may further our knowledge of how airway colonization can result in infection and allograft loss. Surveillance, early diagnosis, and aggressive antimicrobial therapy of BI is critical in LTRs. Antibiotic resistance is a major barrier to successful management of these infections. The availability of new agents for MDR Gram-negatives may improve outcomes. Other new therapies, such as bacteriophage therapy, show promise for the future. Finally, it is important to prevent infections through peri-transplant prophylaxis, vaccination, and infection control measures.

show abstract

Section: Vaccinationsupporting

confidence: 70%

Bacterial infections in lung transplantation

McCort¹,

MacKenzie²,

Pursell³

et al. 2021

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Although it was uncertain whether vaccination would protect agammaglobulinaemic or hypogammaglobulinaemic patients, they were recommended for pH1N1 mass vaccination in Norway. This decision was made based on previous experience with inactivated influenza vaccines, which are considered safe, also for use in immunocompromised patients [19–21]. The pH1N1 vaccine formulation consisted of an H1N1 split virus vaccine (X179a) formulated with the oil‐in‐water adjuvant AS03 (GlaxoSmithKline, Belgium).…”

Section: Introductionmentioning

confidence: 99%

Pandemic Influenza Vaccination Elicits Influenza‐Specific CD4⁺ Th1‐cell Responses in Hypogammaglobulinaemic Patients: Four case reports

et al. 2011

View full text Add to dashboard Cite

In these case reports, we investigated pandemic influenza 2009 vaccination of primary hypogammaglobulinaemic patients. Three combined variable immunodeficiency (CVID) patients and one X‐linked agammaglobulinaemia (XLA) patient were vaccinated with the pandemic vaccine A/California/7/2009 (H1N1)‐like split virus (X179a) adjuvanted with the oil‐in‐water emulsion AS03. Subsequently, serum and peripheral blood mononuclear cells were sampled and used to measure the haemagglutination inhibition (HI) and antibody‐secreting cell (ASC) responses. In addition, the IFN‐γ, IL‐2 and TNF‐α producing CD4+ Th1‐cell response was determined as these cytokines are important indicators of cell‐mediated immunity. Two of the CVID patients responded to vaccination as determined by a >4‐fold rise in HI antibodies. These subjects also had influenza‐specific ASC numbers, which, albeit low, were higher than prevaccination levels. In addition, vaccination induced CD4+ Th1‐cell responses in both the XLA patient and the CVID patients, although the frequency of influenza‐responsive cells varied amongst the patients. These results suggest that hypogammaglobulinaemia patients can mount a CD4+ Th1 cell‐mediated response to influenza vaccination and, additionally, that influenza vaccination of some hypogammaglobulinaemia patients can produce an influenza‐specific humoral immune response. The findings should be confirmed in larger clinical studies.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Safety and efficacy of influenza vaccination in renal transplant recipients

Cited by 3 publications

References 4 publications

Bacterial infections in lung transplantation

Bacterial infections in lung transplantation

Pandemic Influenza Vaccination Elicits Influenza‐Specific CD4⁺ Th1‐cell Responses in Hypogammaglobulinaemic Patients: Four case reports

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About

Safety and efficacy of influenza vaccination in renal transplant recipients

Cited by 3 publications

References 4 publications

Bacterial infections in lung transplantation

Bacterial infections in lung transplantation

Pandemic Influenza Vaccination Elicits Influenza‐Specific CD4+ Th1‐cell Responses in Hypogammaglobulinaemic Patients: Four case reports

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About

Pandemic Influenza Vaccination Elicits Influenza‐Specific CD4⁺ Th1‐cell Responses in Hypogammaglobulinaemic Patients: Four case reports